A novel biomarker combination predicts cognitive decline in preclinical Alzheimer’s disease

Takeaway

  • Entorhinal hypometabolism and hippocampal volume are independently linked to cognitive decline in clinically normal adults with high-amyloid burden.

Why this matters

  • These important findings show that entorhinal hypometabolism is a strong and independent predictor of subsequent cognitive decline in people with preclinical Alzheimer's disease.

  • Together with amyloid and tau-positron emission tomography, fluorodeoxyglucose is a potentially useful biomarker that would permit enriched clinical trials in people with Alzheimer’s disease pathology at high risk of rapid cognitive decline.